Natural Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Review

被引：3

作者：

Singh, Sonia ^{[1
]}

Sharma, Himanshu ^{[2
]}

Ramankutty, Raghavan ^{[3
]}

Ramaswamy, Sarada ^{[3
]}

Agrawal, Nitin ^{[4
]}

机构：

[1] GLA Univ, Inst Pharmaceut Res, Mathura 281406, Uttar Pradesh, India

[2] GLA Univ, Dept Comp Engn & Applicat, Mathura 281406, Uttar Pradesh, India

[3] Datha Ayuryoga Int Hlth Inst, DOO, Podgorica, Montenegro

[4] Raja Balwant Singh Engn Tech Campus, Fac Pharm, Agra 283105, Uttar Pradesh, India

来源：

COMBINATORIAL CHEMISTRY & HIGH THROUGHPUT SCREENING | 2023年 / 26卷 / 15期

关键词：

PCSK9; LDL; cholesterol; inhibitors; monoclonal antibodies; ER; DENSITY-LIPOPROTEIN RECEPTOR; LUPIN PROTEIN; PCSK9; EXPRESSION; GREEN TEA; EPIGALLOCATECHIN GALLATE; INSULIN-RESISTANCE; GENE-EXPRESSION; BERBERINE; CHOLESTEROL; PHARMACOKINETICS;

D O I：

10.2174/1386207326666230627122630

中图分类号：

Q5 [生物化学];

学科分类号：

071010 ; 081704 ;

摘要：

PCSK9 (proprotein convertase subtilisin/kexin type 9) is an enzyme that helps to reduce cardiovascular events. This clinical result is attributable primarily to the crucial involvement of PCSK9 in regulating the low-density lipoprotein cholesterol level. Because oral anti-PCSK9 medications have yet to be available, the benefits of this unique treatment approach have been diminished. Identifying naturally occurring PCSK9 inhibitors may lead to considerable progress in this regard. These inhibitors serve as a starting point for producing oral and effective components that could be used with statins to boost the proportion of patients who achieve their LDL-cholesterol goals. In this review, we have briefly summarised the recent information regarding natural components or extracts that have been shown to inhibit PCSK9 activity.

引用

页码：2668 / 2678

页数：11

共 50 条

[1] A short review of proprotein convertase subtilisin/kexin type 9 inhibitors
Alali, Rudaynah A.
[J]. REVIEWS IN CARDIOVASCULAR MEDICINE, 2019, 20 (01) : 1 - 8
[2] Proprotein Convertase subtilisin Kexin 9 Inhibitors
Pirillo, Angela
Catapano, Alberico Luigi
[J]. CARDIOLOGY CLINICS, 2018, 36 (02) : 241 - +
[3] Lipoprotein(a) and proprotein convertase subtilisin/kexin type 9 inhibitors
Julius U.
Tselmin S.
Schatz U.
Fischer S.
Bornstein S.R.
[J]. Clinical Research in Cardiology Supplements, 2019, 14 (Suppl 1) : 45 - 50
[4] Lipoprotein(a) and inhibitors of proprotein convertase subtilisin/kexin type 9
Kotani, Kazuhiko
Banach, Maciej
[J]. JOURNAL OF THORACIC DISEASE, 2017, 9 (01) : E78 - E82
[5] Proprotein Convertase Subtilisin/Kexin Type 9
Lu
Daugherty
[J]. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2016, 36 (04) : E32 - E32
[6] Pleiotropic effects of proprotein convertase subtilisin/kexin type 9 inhibitors?
Filippatos, Theodosios D.
Christopoulou, Eliza C.
Elisaf, Moses S.
[J]. CURRENT OPINION IN LIPIDOLOGY, 2018, 29 (04) : 333 - 339
[7] Proprotein convertase subtilisin/kexin type 9 (PCSK9) and inhibitors
Avci, Ahmet
Demir, Kenan
Altunkeser, Bulent Behlul
[J]. TURK KARDIYOLOJI DERNEGI ARSIVI-ARCHIVES OF THE TURKISH SOCIETY OF CARDIOLOGY, 2014, 42 : 56 - 67
[8] Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Brief Overview
Noel, Zachary R.
Beavers, Craig J.
[J]. AMERICAN JOURNAL OF MEDICINE, 2017, 130 (02): : 229.e1 - 229.e4
[9] Advances in the field of proprotein convertase subtilisin kexin type 9 inhibitors
Eisen, Alon
Giugliano, Robert P.
[J]. CURRENT OPINION IN CARDIOLOGY, 2016, 31 (06) : 644 - 653
[10] Proprotein convertase subtilisin/kexin type 9 inhibition
Marais, David A.
Blom, Dirk J.
Petrides, Francine
Goueffic, Yann
Lambert, Gilles
[J]. CURRENT OPINION IN LIPIDOLOGY, 2012, 23 (06) : 511 - 517

← 1 2 3 4 5 →